To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate treatment of patients with metastatic prostate cancer (mPC) and the clinical utility of agents that could signiícantly impact patient outcomes. PARP inhibitors, which are one of the most promising new classes of agents for mPC, oìer the potential for better survival, but clinicians require education to address the challenges of integrating these agents into practice. This program will review the latest evidence on genetic testing to guide treatment selection, other methods for personalizing therapy, the indications for PARP inhibitor-based monotherapy and combination therapy for mPC, and how to manage safety concerns. After attending this program, clinicians will be prepared with a thorough knowledge of the current landscape and the applications of PARP inhibitors within the health care system.
- Provider:Medical Education Resources
- Activity Link: https://mycme.com
- Start Date: 2025-01-03 06:00:00
- End Date: 2025-01-03 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 50000.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 50000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all